---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-09-21T03:36:04.160692'
end_time: '2026-09-21T03:58:21.557983'
duration_seconds: 1337.4
template_file: templates/gene_hypothesis_deep_research.md
template_variables:
  organism: ANOGA
  gene: PGRPLB
  gene_symbol: PGRPLB
  uniprot_accession: F5HMW5
  taxon_id: NCBITaxon:7165
  taxon_label: Anopheles gambiae
  focus_type: function_assignment
  hypothesis_slug: immune-receptor-defense-and-secretion
  hypothesis_text: Anopheles gambiae PGRPLB (F5HMW5) has peptidoglycan immune receptor
    activity, contributes to defense against Gram-positive bacteria, or localizes
    extracellularly. Evaluate each separately from amidase activity. Identify whether
    direct peptidoglycan binding and catalytic depletion mediate sensing/signaling,
    immune suppression or another role. Compare actual tested peptidoglycan chemotypes
    and bacterial species rather than equating DAP-versus-Lys specificity with an
    absolute Gram classification. Assess N-terminal topology and experimentally demonstrated
    secreted or membrane pools, including isoforms.
  term_context: No specific term context supplied.
  reference_context: No specific reference context supplied.
  source_file: genes/ANOGA/PGRPLB/PGRPLB-ai-review.yaml
  source_selector: free-text
  source_context_yaml: "hypothesis: Anopheles gambiae PGRPLB (F5HMW5) has peptidoglycan\
    \ immune receptor activity, contributes\n  to defense against Gram-positive bacteria,\
    \ or localizes extracellularly. Evaluate each separately from\n  amidase activity.\
    \ Identify whether direct peptidoglycan binding and catalytic depletion mediate\
    \ sensing/signaling,\n  immune suppression or another role. Compare actual tested\
    \ peptidoglycan chemotypes and bacterial species\n  rather than equating DAP-versus-Lys\
    \ specificity with an absolute Gram classification. Assess N-terminal\n  topology\
    \ and experimentally demonstrated secreted or membrane pools, including isoforms.\n\
    focus_type: function_assignment\ncontext: []\nreference_id: []"
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 3
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 7200
    save_artifacts: true
    artifact_max_bytes: 5242880
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# AIGR Gene Hypothesis Deep Research

You are evaluating one focused gene curation hypothesis for AI Gene Review.
This is not a general gene overview. Use the seed hypothesis and source context
below to search for evidence that supports, refutes, narrows, or competes with
the proposed curation decision.

## Target Gene

- **Organism code:** ANOGA
- **Taxon:** Anopheles gambiae (NCBITaxon:7165)
- **Gene directory:** PGRPLB
- **Gene symbol:** PGRPLB
- **UniProt accession:** F5HMW5

## Focus

- **Focus type:** function_assignment
- **Hypothesis slug:** immune-receptor-defense-and-secretion
- **Source file:** genes/ANOGA/PGRPLB/PGRPLB-ai-review.yaml
- **Source selector:** free-text

## Seed Hypothesis

Anopheles gambiae PGRPLB (F5HMW5) has peptidoglycan immune receptor activity, contributes to defense against Gram-positive bacteria, or localizes extracellularly. Evaluate each separately from amidase activity. Identify whether direct peptidoglycan binding and catalytic depletion mediate sensing/signaling, immune suppression or another role. Compare actual tested peptidoglycan chemotypes and bacterial species rather than equating DAP-versus-Lys specificity with an absolute Gram classification. Assess N-terminal topology and experimentally demonstrated secreted or membrane pools, including isoforms.

## Term and Decision Context

No specific term context supplied.

## Reference Context

No specific reference context supplied.

## Source Context YAML

```yaml
hypothesis: Anopheles gambiae PGRPLB (F5HMW5) has peptidoglycan immune receptor activity, contributes
  to defense against Gram-positive bacteria, or localizes extracellularly. Evaluate each separately from
  amidase activity. Identify whether direct peptidoglycan binding and catalytic depletion mediate sensing/signaling,
  immune suppression or another role. Compare actual tested peptidoglycan chemotypes and bacterial species
  rather than equating DAP-versus-Lys specificity with an absolute Gram classification. Assess N-terminal
  topology and experimentally demonstrated secreted or membrane pools, including isoforms.
focus_type: function_assignment
context: []
reference_id: []
```

## Research Objective

Build a focused report that helps a curator decide whether this hypothesis
should affect the gene review. Address the focus type directly:

1. For an existing GO annotation decision, evaluate whether the current action
   is justified, too strong, too weak, or should change.
2. For a proposed replacement or new GO term, evaluate whether the term is
   biologically supported, too broad, too narrow, or missing key qualifiers.
3. For a computational prediction, evaluate whether the prediction is correct,
   less precise than existing knowledge, uncertain, or likely wrong because of
   paralog overannotation, frequency bias, pathway context, or in vitro-only
   activity.
4. For a core-function hypothesis, evaluate whether the proposed activity,
   process, and location represent the gene product's primary function rather
   than a downstream effect, pleiotropic phenotype, or context-specific role.
5. For a function-assignment hypothesis, evaluate whether the gene product
   directly has the stated GO term/function. Treat the prior review action, if
   any, as intentionally blinded unless it appears in the supplied context.

Use primary literature whenever possible. Prefer PMID citations and include DOI
citations when no PMID is available. Treat reviews and database records as
orientation unless they contain directly relevant synthesized evidence that is
clearly labeled as review-level or database-level support.

Evaluate the hypothesis from the supplied seed context, primary literature, and
publicly accessible bioinformatics resources. Local `*-bioinformatics` analyses,
when they already exist in the repository, are intentionally withheld from this
prompt so the report can be compared against them after the run. Use public
sequence, domain, structure, orthology, localization, interaction, or dataset
checks when they are useful for the specific hypothesis. If a resource or tool
cannot be accessed programmatically, say so plainly; never fabricate a result.
Report computational results conservatively and distinguish direct results from
inference.

## Required Output

### Executive Judgment

Give a concise verdict: supported, partially supported, unresolved, weakly
supported, over-annotated, or refuted. Explain the reasoning and the most
important caveats.

### Evidence Matrix

Create a table with one row per important evidence item:

- Citation (PMID preferred)
- Evidence type (direct assay, mutant phenotype, localization, interaction,
  structural/evolutionary, computational, review/database)
- Supports / refutes / qualifies / competing
- Claim tested
- Key finding
- Organism, tissue, cell type, or assay context
- Confidence and limitations

### GO Curation Implications

State the likely curation action as a lead requiring curator verification. If
GO terms are involved, explain whether the evidence supports an MF, BP, or CC
term, and whether the term should be retained, removed, generalized, made more
specific, or treated as non-core. Avoid using "protein binding" as a final
recommendation unless no more informative term is supported.

### Mechanistic Scope

Describe the immediate molecular or cellular function being tested. Separate
direct gene-product activity from downstream phenotypes, pathway consequences,
developmental outcomes, disease manifestations, or effects inferred only from
loss of function.

### Conflicts and Alternatives

Identify evidence that conflicts with the seed hypothesis or suggests an
alternative interpretation, including paralog confusion, organism-specific
differences, isoform-specific findings, experimental artifacts, or database
carry-over.

### Knowledge Gaps

List explicit uncertainties that matter for curation. For each gap, state what
was checked, why the gap matters, and what evidence or experiment would resolve
it.

### Discriminating Tests

Recommend concrete assays, perturbations, datasets, or comparative analyses that
would most efficiently distinguish this hypothesis from alternatives.

### Curation Leads

Provide candidate updates for the review, clearly labeled as leads requiring
curator verification. Include candidate references with exact snippets to verify,
candidate replacement or new GO terms, possible action changes, suggested
questions, and suggested experiments.

If the provider supports artifacts, save provenance for any analysis you run — the
executed code together with its output (computed values, plot, or table), not just
a summary figure — alongside artifact-friendly tables such as an evidence matrix,
GO decision table, or comparison table. Genuine computed provenance is more
valuable than a hand-drawn summary, and you must not synthesize a figure that
implies an analysis you did not actually run. These artifacts are important
provenance for hypothesis-level review.


## Output

# PGRPLB (Anopheles gambiae, UniProt F5HMW5) — Hypothesis Deep Research

**Focus:** function_assignment · **Hypothesis slug:** immune-receptor-defense-and-secretion
**Source:** genes/ANOGA/PGRPLB/PGRPLB-ai-review.yaml (free-text)

## Seed hypothesis (restated)
F5HMW5 (1) has peptidoglycan **immune receptor activity**, (2) contributes to **defense against Gram-positive bacteria**, and/or (3) **localizes extracellularly** — each to be evaluated *separately from* amidase activity.

Each sub-claim maps precisely onto an existing **IBA-only** (phylogenetically inferred) GO annotation on F5HMW5:
(1) → **GO:0016019** peptidoglycan receptor activity (MF, IBA); (2) → **GO:0050830** defense response to Gram-positive bacterium (BP, IBA); (3) → **GO:0005576** extracellular region (CC, IBA).

---

## Executive Judgment

- **Sub-claim 1 — peptidoglycan immune *receptor* activity (GO:0016019): OVER-ANNOTATED / refuted as a core function.** F5HMW5 is a bona fide *catalytic* amidase of the PGRP-LB subfamily (PANTHER SF77), with a fully intact zinc/catalytic-Cys active site that aligns residue-for-residue with the biochemically characterized Drosophila PGRP-LB amidase. In this pathway the sensing receptor is **PGRP-LC** (Anopheles PGRPLC), not PGRP-LB. The GO:0016019 IBA is propagated from a mixed PANTHER node containing recognition PGRPs/mammalian PGLYRPs — a classic paralog/family over-annotation. PGRP-LB binds peptidoglycan as a **substrate for catalysis**, not for signal transduction.

- **Sub-claim 2 — defense against Gram-positive bacteria (GO:0050830): weakly supported / mis-directed.** PGRP-LB is a **negative regulator** of the Imd pathway (dampens immunity), and its amidase specifically degrades **DAP-type (Gram-negative) peptidoglycan**. In Anopheles, PGRPLB *promotes* permissiveness to *P. falciparum* — i.e., it suppresses rather than mediates defense. A "defense response to Gram-positive bacterium" term is questionable on both chemotype (DAP vs Lys) and sign (suppressor vs effector).

- **Sub-claim 3 — extracellular localization (GO:0005576): partially supported (orthology), unresolved for this accession.** The Drosophila ortholog is experimentally secreted, but F5HMW5 carries **both "Signal" and "Transmembrane" keywords** with a predicted N-terminal helix (7–23); the N-terminus could be a cleaved signal peptide (secreted) or an uncleaved signal anchor (type-II membrane). Crucially for curation: F5HMW5 = **AGAP001212** with a **single annotated transcript** (AGAP001212-RA), **protein existence PE3 (inferred from homology)**, and the transmembrane call is a **prediction-only (SAM automatic)** annotation with no experimental support. The multi-isoform localization argument from *Drosophila* therefore does not transfer, and localization is best treated as an orthology-based lead rather than an established fact.

- **Anopheles-specific receptor architecture (Iteration 3):** In *Anopheles*, the peptidoglycan **receptor** of the Imd pathway is **PGRPLC** (transmembrane; binds DAP-type PGN by pull-down; PMID 31760136), with PGRP-S1 serving Toll (PMID 39761205). This species-matched evidence assigns "peptidoglycan receptor activity" to PGRPLC, **not** PGRPLB — directly reinforcing that GO:0016019 on F5HMW5 is paralog-borrowed over-annotation.

**Overall verdict: the seed hypothesis is largely NOT supported as stated.** The gene product's primary, best-supported function is a **secreted/extracellular DAP-type peptidoglycan amidase that negatively regulates the Imd immune response** — not a signaling receptor and not a Gram-positive defense effector.

---

## Evidence Matrix

| Citation | Evidence type | Supports/Refutes | Claim tested | Key finding | Context | Confidence & limitations |
|---|---|---|---|---|---|---|
| UniProt F5HMW5 (this run) | Computational (domain/sequence) | Refutes receptor; supports amidase | Is F5HMW5 a catalytic amidase or a receptor? | Pfam Amidase_2 (PF01510); PANTHER PGRP-LB (SF77); intact catalytic Cys (ECPG, C178) + zinc-His (GAH/GHR); near-identical to Dros PGRP-LB catalytic core | A. gambiae protein, 205 aa | High for catalytic assignment; in-silico active site (no direct enzyme assay on F5HMW5) |
| PMID 16618604 (Zaidman-Rémy 2006) | Direct assay + localization | Refutes Gram-positive & receptor; qualifies secretion | Ortholog function/localization/specificity | "PGRP-LB is a secreted protein"; "amidase that specifically degrades gram-negative bacteria peptidoglycan"; "downregulates the Imd pathway" | Drosophila | High; ortholog (not A. gambiae) |
| PMID 28494453 (Gendrin 2017) | Mutant/RNAi phenotype | Refutes defense-effector & receptor | In-vivo role of Anopheles PGRPLB | PGRPLC is the receptor activating Imd; PGRPLB negatively regulates Imd; "PGRPLB promotes mosquito permissiveness to P. falciparum" | Anopheles coluzzii/gambiae, gut/systemic | High; species-matched primary evidence |
| PMID 22118526 (Paredes 2011) | Mutant phenotype | Supports negative-regulator BP | Is PGRP-LB a negative regulator? | Confirms "PGRP-LB as a negative regulator of the Imd pathway"; catalytic PGRPs scavenge peptidoglycan | Drosophila | High; ortholog |
| PMID 31760136 (Rodgers/Gendrin 2020) | Interaction + phenotype | Refutes receptor claim for LB | Which Anopheles PGRP is the PGN receptor? | PGRPLC is "the transmembrane receptor of the Imd pathway"; PGRPLC isoforms pulled down with **DAP-type** peptidoglycan (LC1/LC3 polymeric, LC2/LC3 TCT) | Anopheles coluzzii midgut | High; species-matched; concerns LC (assigns receptor role away from LB) |
| PMID 39761205 (Song 2025) | Mutant phenotype | Qualifies (chemotype/receptors) | Which receptors sense PGN in mosquito gut? | Mosquito PGN receptors are Pgrp-lc (IMD) and Pgrp-s1 (Toll); both DAP-PGN and Lys-PGN present in gut | Anopheles stephensi gut | Medium-High; supports receptor≠LB and chemotype nuance |
| UniProt xref (this run, Iter 3) | Database | Qualifies localization | Gene identity, isoforms, evidence level of F5HMW5 | F5HMW5 = VectorBase/Ensembl **AGAP001212** (single transcript AGAP001212-RA); protein existence **PE3 (inferred from homology)**; N-terminal TM 7-23 is **SAM automatic prediction** only | A. gambiae | High for identity; topology prediction-only |
| Comparative alignment (this run, Iter 2) | Structural/evolutionary (computational) | Refutes receptor; supports amidase | Does F5HMW5 keep catalytic vs recognition features? | F5HMW5 most identical to catalytic amidases (PGLYRP2 57.8%, PGRP-LB 56.7% > recognition LC 47.8%, SA 36.7%); diagnostic catalytic Cys (ECPG/C178) conserved with PGRP-LB & PGLYRP2, diverged in recognition PGRPs | A. gambiae protein vs PGRP panel | Medium-High; NW identity over aligned columns is approximate; SC1 anchor caveat noted |
| QuickGO annotations F5HMW5 (this run) | Database | Context | What is currently annotated? | GO:0016019, GO:0050830, GO:0005576 are **IBA-only**; amidase (GO:0008745), Zn (GO:0008270), PGN binding (GO:0042834), PGN catabolism (GO:0009253) also present | — | Database orientation; IBA nodes mix recognition + catalytic PGRPs |

---

## Comparative Sequence Provenance (Iteration 2 — executed)

**Global Needleman–Wunsch % identity of F5HMW5 vs a PGRP panel** (identity over aligned columns):

| Reference | Class | % identity to F5HMW5 |
|---|---|---|
| Human PGLYRP2 (Q96PD5) | catalytic amidase | 57.8 |
| Drosophila PGRP-LB (Q8INK6) | catalytic amidase | 56.7 |
| Drosophila PGRP-LC (Q9GNK5) | recognition receptor | 47.8 |
| Drosophila PGRP-SC1 (Q9VXN9) | catalytic amidase | 44.3 |
| Drosophila PGRP-SA (Q9VYX7) | recognition (Lys-type) | 36.7 |

**Diagnostic catalytic-cysteine motif** (anchored on the zinc-His `GHR`, C-terminal catalytic region):

| Protein | Class | Motif | Catalytic Cys |
|---|---|---|---|
| F5HMW5 (target) | catalytic | `GHRQVRTTECPGDRL` (C178) | present |
| Drosophila PGRP-LB | catalytic | `GHRQVRDTECPGGRL` | present |
| Human PGLYRP2 | catalytic | `GHRQLVRTDCPGDALF` | present |
| Drosophila PGRP-LC | recognition | motif diverged (no aligned Cys) | absent |
| Drosophila PGRP-SA | recognition | motif diverged (no aligned Cys) | absent |

F5HMW5 retains the full catalytic set: HH doublet (H60/H61), zinc-His `GAH` (H118), catalytic His `GHR` (H171), catalytic Cys `ECPG` (C178), plus groove Tyr (Y56/Y63/Y69). *Caveat:* the strict `GHR` anchor also failed for catalytic PGRP-SC1 (divergent motif window), so motif-absence alone is not proof of non-catalysis for every paralog; the catalytic-vs-recognition contrast rests on the aligned catalytic Cys, consistent with published PGRP biochemistry.

---

## GO Curation Implications (leads — require curator verification)

| GO ID | Term | Aspect | Current evidence | Recommended action |
|---|---|---|---|---|
| GO:0008745 | N-acetylmuramoyl-L-alanine amidase activity | MF | IEA+IBA | **Retain — core MF** (intact catalytic residues + ortholog assays) |
| GO:0008270 | zinc ion binding | MF | IEA | **Retain** (metalloamidase; supported by active site) |
| GO:0042834 | peptidoglycan binding | MF | IEA | **Retain** as substrate binding (preferred over "receptor activity") |
| GO:0016019 | peptidoglycan **receptor** activity | MF | IBA only | **Remove / do-not-assert (NOT)** — over-annotated via mixed PANTHER node; receptor role belongs to PGRP-LC |
| GO:0009253 | peptidoglycan catabolic process | BP | IEA | **Retain — core BP** |
| GO:0045824 (candidate) | negative regulation of innate immune response | BP | not present | **Add (lead)** — species-matched phenotype (Gendrin 2017; Paredes 2011) |
| GO:0050830 | defense response to Gram-positive bacterium | BP | IBA only | **Remove / non-core** — wrong chemotype (DAP/Gram-negative) and wrong sign (suppressor) |
| GO:0005576 | extracellular region | CC | IBA | **Retain as orthology lead**, flag N-terminal signal/TM ambiguity |
| GO:0016020 | membrane | CC | (keyword only) | **Do not assert** without experimental support (prediction artifact risk) |

Avoid "protein binding" as an endpoint; the informative MF is **amidase activity** with **peptidoglycan binding** as substrate recognition.

---

## Mechanistic Scope
Immediate molecular function tested: enzymatic **N-acetylmuramoyl-L-alanine amidase** cleavage of the lactyl-amide bond in peptidoglycan (zinc-dependent), depleting DAP-type muropeptides. Downstream/consequential (not the direct MF): reduced Imd/PGRP-LC signaling, immune tolerance to gut microbiota, and increased *Plasmodium* permissiveness. The seed's "receptor activity" and "Gram-positive defense" are downstream/pathway framings that do not correspond to the gene product's direct biochemical activity; "receptor activity" is additionally a paralog-borrowed function.

## Conflicts and Alternatives
- **Paralog confusion:** GO:0016019 and part of GO:0050830 originate from an IBA node combining recognition PGRPs (PGRP-LC/SA-type, mammalian PGLYRP1/3/4) with catalytic ones; F5HMW5 is catalytic. Receptor activity belongs to PGRP-LC.
- **Sign reversal:** Loss-of-function *increases* immunity/parasite clearance, so LB is protective *of the microbe/parasite context*, not a defense effector.
- **Chemotype vs Gram class:** DAP-type PGN occurs in Gram-negative bacteria *and* Bacillus (Gram-positive); "Gram-positive defense" is not equivalent to Lys-type specificity and is not the tested chemotype.
- **Isoform/topology:** dual signal/TM prediction implies possible membrane vs secreted isoforms; extracellular pool is inferred, not shown for F5HMW5.

## Knowledge Gaps
1. **Direct enzymatic assay on F5HMW5** — checked: none found; matters because amidase assignment currently rests on sequence + orthology. Resolve with recombinant amidase activity on DAP- vs Lys-type PGN.
2. **Substrate specificity of F5HMW5** — checked ortholog (DAP-type); matters for GO:0050830. Resolve by muropeptide-resolved activity assay.
3. **N-terminal processing / localization of F5HMW5** — checked: UniProt/Ensembl show a single transcript (AGAP001212-RA), PE3 (homology-inferred), and a prediction-only (SAM) TM helix; no experimental localization exists. Matters because GO:0005576 vs membrane cannot be decided from current data. Resolve by SignalP/DeepTMHMM analysis plus an N-terminomics/secretion (surface vs supernatant) assay on A. gambiae PGRPLB.
4. **Catalytic-dead vs wild-type rescue in Anopheles** — matters to prove the negative-regulation is amidase-dependent.

## Discriminating Tests
- Recombinant F5HMW5 amidase assay on purified DAP-type vs Lys-type PGN (distinguishes amidase vs "receptor"; chemotype specificity).
- Catalytic-Cys (C178A) mutant: loss of amidase and loss of Imd down-regulation would confirm mechanism.
- Secretion/topology: signal-peptide cleavage / surface-vs-supernatant fractionation across isoforms.
- Epistasis with PGRPLC knockdown to confirm LB acts by depleting the PGRP-LC ligand.

## Curation Leads (verify)
- **Remove/NOT** GO:0016019 (peptidoglycan receptor activity) on F5HMW5 — IBA over-annotation; cite PMID 28494453 (PGRPLC is the receptor) and PMID 16618604 (LB is a catalytic amidase).
- **Remove/downgrade** GO:0050830 (defense response to Gram-positive bacterium); consider **add GO:0045824** (negative regulation of innate immune response) with PMID 28494453 / 22118526.
- **Retain** GO:0008745, GO:0008270, GO:0042834, GO:0009253 as core.
- **Retain** GO:0005576 as orthology lead; annotate the N-terminal signal/TM ambiguity; do not assert integral-membrane CC.
- Candidate references with snippets to verify: PMID 16618604 "PGRP-LB is a secreted protein"; "amidase that specifically degrades gram-negative bacteria peptidoglycan"; PMID 28494453 "PGRPLB promotes mosquito permissiveness to P. falciparum".

## Limitations
Direct biochemical/localization data are for the Drosophila ortholog; A. gambiae in-vivo evidence (Gendrin 2017) is genetic/RNAi. No F5HMW5-specific enzyme or localization assay was located. Sequence/active-site analysis is computational (public UniProt/PANTHER/Pfam). No fabricated results.


## Artifacts

- [OpenScientist final report](openscientist_artifacts/final_report.html)
- [OpenScientist final report](openscientist_artifacts/final_report.pdf)